Category: News
-
“When Lung Cancer Is Diagnosed, Fast Blood Tests Can Help Save Lives”
One News video
-
GenomeWeb: Biodesix Receives Two Positive Coverage Decisions for Veristrat
“Biodesix said today BlueCross BlueShield (BCBS) of Florida and Health Care Services Corporation (HCSC) have agreed to cover its Veristrat lung cancer test.” Read the full story here.
-
Expansion into Genomics | Biodesix
“Proteomic-based tests remain for many clinicians a somewhat exotic option. On other hand, doctors are often more familiar and comfortable with genetic tests, and so Biodesix’s GeneStrat, which uses BioRad’s droplet digital PCR to identify clinically actionable mutations in EGFR, KRAS, ALK, and BRAF in free tumor nucleic acid, has to an extent helped the…
-
Diagnostic Advances for Novel Drug | Biodesix
Innovationews – “Biodesix Inc. announced new clinical findings that show its novel investigational test, BDX008 – based on profiling serum proteins – identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumb therapy.” Read the full story.
-
Biodesix Fights Cancer with Speed
Denver Business Journal – “Fastest Growing Companies” – Biodesix Fights Cancer With Speed
-
Biodesix: 216 of the Inc500 for 2015
“Biodesix discovers and commercializes cancer tests that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile….” Read more at inc.com
-
United Healthcare Approves Coverage for Biodesix’ VeriStrat Test
Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from United Healthcare (NYSE: UNH), one of the largest commercial insurance company in the US, with a published 44.7 million covered lives. In its Medical Policy (#2015T0535EE), United Healthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung…
-
Study: Better NSCLC Outcomes with Proteomic Test
The VeriStrat proteomic test, when used to help guide treatment of patients with advanced non-small cell lung cancer, improves overall survival and decreases medical costs in the U.S. payer system, said a study published recently in the journal Lung Cancer.